Categories: Health

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

 | Source: Fulcrum Therapeutics, Inc.

CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum granted the new employee 35,000 options to purchase shares of the company’s common stock at an exercise price of $7.27 per share, the closing price per share of Fulcrum’s common stock as reported on the grant effective date, September 8, 2025. Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to the applicable employee’s continued service with the company through the applicable vesting dates.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of SCD. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.

Contact:

Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856

GlobeNews Wire

Recent Posts

Universal Declaration adopted to strengthen integrity in sport

24 October 2025 - More than 400 leaders from the Olympic Movement, governments, inter-governmental agencies and…

1 hour ago

Andamanda Phuket Ranked in Trip Best 2025 Global Top 100 – A Must-Visit for Indian Families

Offering much more than just beaches, Andamanda Phuket — a Thai mythology-inspired water park — was recently…

4 hours ago

From Grandstand to Every Person: Sting Makes F1 Dream a Reality for Fans

In a bold move that fuses cinema, culture, and adrenaline, Sting® Energy, PepsiCo India’s high-voltage…

4 hours ago

Bybit Bridges the Future of Finance and Music at Tomorrowland Brasil 2025

Bybit Card brings real-world crypto utility to 45,000 festivalgoers at "Portal to the Future" stage…

4 hours ago

Startek honored with the AAA DI-verse Certification for disability inclusion excellence

Recognition marks Startek's commitment to building an inclusive and accessible workplace for all MUMBAI, India, Oct.…

4 hours ago

COTHM Pakistan and MindHYVE.ai Forge Strategic Partnership to Pioneer AI-Powered Hospitality Education

LAHORE, Pakistan, Oct. 24, 2025 /PRNewswire/ -- The College of Tourism & Hotel Management (COTHM…

4 hours ago